Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis

Intensive Care Medicine

Volumn 42, Issue 10, 2016, Pages 1535-1545

  Abdul Aziz, Mohd H ^a,b   Sulaiman, Helmi ^c   Mat Nor, Mohd Basri ^b   Rai, Vineya ^c   Wong, Kang K ^c   Hasan, Mohd S ^c   Abd Rahman, Azrin N ^a,b   Jamal, Janattul A ^d   Wallis, Steven C ^a   Lipman, Jeffrey ^a,e   Staatz, Christine E ^a,f   Roberts, Jason A ^a,e  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b INTERNATIONAL ISLAMIC UNIVERSITY MALAYSIA   (Malaysia)

^c UNIVERSITY OF MALAYA   (Malaysia)

^d HOSPITAL TENGKU AMPUAN AFZAN   (Malaysia)

^e ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^f Australian Centre of Pharmacometrics   (Australia)

Author keywords

Antibiotics; Critically ill; Intermittent bolus; Pharmacodynamics; Pharmacokinetics; Prolonged infusion

Indexed keywords

CEFEPIME; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; ANTIINFECTIVE AGENT; BETA LACTAM;

ACINETOBACTER BAUMANNII; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL OUTCOME; COHORT ANALYSIS; CONTINUOUS INFUSION; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG FATALITY; DRUG INTERMITTENT THERAPY; DRUG PROTEIN BINDING; FEMALE; HUMAN; KAPLAN MEIER METHOD; KLEBSIELLA PNEUMONIAE; LENGTH OF STAY; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; NONHUMAN; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL; RENAL REPLACEMENT THERAPY; SEPSIS; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; CRITICAL ILLNESS; INTENSIVE CARE; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; NONPARAMETRIC TEST; PATHOPHYSIOLOGY; PROCEDURES;

ADULT; ANTI-BACTERIAL AGENTS; BETA-LACTAMS; CHI-SQUARE DISTRIBUTION; CRITICAL CARE; CRITICAL ILLNESS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SEPSIS; STATISTICS, NONPARAMETRIC;

EID: 84954145897     PISSN: 03424642     EISSN: 14321238     Source Type: Journal    
DOI: 10.1007/s00134-015-4188-0     Document Type: Article

References (40)

1. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb SA, Beale RJ, Vincent JL, Moreno R (2013) Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 41:580–637
2. Roberts JA, Abdul-Aziz MH, Lipman J, Mouton JW, Vinks AA, Felton TW, Hope WW, Farkas A, Neely MN, Schentag JJ, Drusano G, Frey OR, Theuretzbacher U, Kuti JL (2014) Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis 14:498–509
3. Craig WA (1998) Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 26:1–10 (quiz 11–12)
4. Abdul-Aziz MH, Dulhunty JM, Bellomo R, Lipman J, Roberts JA (2012) Continuous beta-lactam infusion in critically ill patients: the clinical evidence. Ann Intensive Care 2:37
5. Abdul-Aziz MH, Lipman J, Mouton JW, Hope WW, Roberts JA (2015) Applying pharmacokinetic/pharmacodynamic principles in critically ill patients: optimizing efficacy and reducing resistance development. Semin Respir Crit Care Med 36:136–153
6. van Zanten AR, Oudijk M, Nohlmans-Paulssen MK, van der Meer YG, Girbes AR, Polderman KH (2007) Continuous vs. intermittent cefotaxime administration in patients with chronic obstructive pulmonary disease and respiratory tract infections: pharmacokinetics/pharmacodynamics, bacterial susceptibility and clinical efficacy. Br J Clin Pharmacol 63:100–109
7. Rafati MR, Rouini MR, Mojtahedzadeh M, Najafi A, Tavakoli H, Gholami K, Fazeli MR (2006) Clinical efficacy of continuous infusion of piperacillin compared with intermittent dosing in septic critically ill patients. Int J Antimicrob Agents 28:122–127
8. Lau WK, Mercer D, Itani KM, Nicolau DP, Kuti JL, Mansfield D, Dana A (2006) Randomized, open-label, comparative study of piperacillin-tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intra-abdominal infection. Antimicrob Agents Chemother 50:3556–3561
9. Georges B, Conil JM, Cougot P, Decun JF, Archambaud M, Seguin T, Chabanon G, Virenque C, Houin G, Saivin S (2005) Cefepime in critically ill patients: continuous infusion vs. an intermittent dosing regimen. Int J Clin Pharmacol Ther 43:360–369
10. Lubasch A, Luck S, Lode H, Mauch H, Lorenz J, Bolcskei P, Welte T (2003) Optimizing ceftazidime pharmacodynamics in patients with acute exacerbation of severe chronic bronchitis. J Antimicrob Chemother 51:659–664
11. Nicolau DP, McNabb J, Lacy MK, Quintiliani R, Nightingale CH (2001) Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia. Int J Antimicrob Agents 17:497–504
12. Angus BJ, Smith MD, Suputtamongkol Y, Mattie H, Walsh AL, Wuthiekanun V, Chaowagul W, White NJ (2000) Pharmacokinetic-pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis. Br J Clin Pharmacol 50:184–191
13. Hanes SD, Wood GC, Herring V, Croce MA, Fabian TC, Pritchard E, Boucher BA (2000) Intermittent and continuous ceftazidime infusion for critically ill trauma patients. Am J Surg 179:436–440
14. Shiu J, Wang E, Tejani AM, Wasdell M (2013) Continuous versus intermittent infusions of antibiotics for the treatment of severe acute infections. Cochrane Database Syst Rev 3:CD008481
15. Roberts JA, Webb S, Paterson D, Ho KM, Lipman J (2009) A systematic review on clinical benefits of continuous administration of beta-lactam antibiotics. Crit Care Med 37:2071–2078
16. Kasiakou SK, Sermaides GJ, Michalopoulos A, Soteriades ES, Falagas ME (2005) Continuous versus intermittent intravenous administration of antibiotics: a meta-analysis of randomised controlled trials. Lancet Infect Dis 5:581–589
17. Dulhunty JM, Roberts JA, Davis JS, Webb SA, Bellomo R, Gomersall C, Shirwadkar C, Eastwood GM, Myburgh J, Paterson DL, Lipman J (2013) Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial. Clin Infect Dis 56:236–244
18. Chytra I, Stepan M, Benes J, Pelnar P, Zidkova A, Bergerova T, Pradl R, Kasal E (2012) Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open-label controlled trial. Crit Care 16:R113
19. Roberts JA, Boots R, Rickard CM, Thomas P, Quinn J, Roberts DM, Richards B, Lipman J (2007) Is continuous infusion ceftriaxone better than once-a-day dosing in intensive care? A randomized controlled pilot study. J Antimicrob Chemother 59:285–291
20. Kiratisin P, Chongthaleong A, Tan TY, Lagamayo E, Roberts S, Garcia J, Davies T (2012) Comparative in vitro activity of carbapenems against major Gram-negative pathogens: results of Asia–Pacific surveillance from the COMPACT II study. Int J Antimicrob Agents 39:311–316
21. Abdul-Aziz M, Sulaiman H, Mat-Nor M, Rai V, Wong K, Hasan M, Wallis S, Lipman J, Staatz C, Roberts J (2015) The BLISS Study: beta-lactam infusion in severe sepsis-randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis in a Malaysian ICU setting. In: 55th interscience conference of antimicrobial agents and chemotherapy (ICAAC), San Diego, 18–21 September 2015
22. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41
23. Knaus WA, Draper EA, Wagner DP, Zimmerman JE (1985) APACHE II: a severity of disease classification system. Crit Care Med 13:818–829
24. Ferreira FL, Bota DP, Bross A, Melot C, Vincent JL (2001) Serial evaluation of the SOFA score to predict outcome in critically ill patients. JAMA 286:1754–1758
25. Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383
26. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ (1981) A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30:239–245
27. McWhinney BC, Wallis SC, Hillister T, Roberts JA, Lipman J, Ungerer JP (2010) Analysis of 12 beta-lactam antibiotics in human plasma by HPLC with ultraviolet detection. J Chromatogr B Analyt Technol Biomed Life Sci 878:2039–2043
28. Food and Drug Administration (2001) Guidance for industry: bioanalytical method validation. FDA, Rockville
29. Wong G, Briscoe S, Adnan S, McWhinney B, Ungerer J, Lipman J, Roberts JA (2013) Protein binding of beta-lactam antibiotics in critically ill patients: can we successfully predict unbound concentrations? Antimicrob Agents Chemother 57:6165–6170
30. Dulhunty JM, Roberts JA, Davis JS, Webb SA, Bellomo R, Gomersall C, Shirwadkar C, Eastwood GM, Myburgh J, Paterson DL, Starr T, Paul SK, Lipman J, BLING II Investigators for the ANZICS Clinical Trials Group (2015) A multicenter randomized trial of continuous versus intermittent beta-lactam infusion in severe sepsis. Am J Respir Crit Care Med 192:1298–1305
31. Abdul-Aziz MH, Lipman J, Akova M, Bassetti M, De Waele JJ, Dimopoulos G, Dulhunty J, Kaukonen KM, Koulenti D, Martin C, Montravers P, Rello J, Rhodes A, Starr T, Wallis SC, Roberts JA, DALI Study Group (2016) Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients (DALI) cohort. J Antimicrob Chemother 71(1):196–207
32. McKinnon PS, Paladino JA, Schentag JJ (2008) Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int J Antimicrob Agents 31:345–351
33. De Waele JJ, Lipman J, Akova M, Bassetti M, Dimopoulos G, Kaukonen M, Koulenti D, Martin C, Montravers P, Rello J, Rhodes A, Udy AA, Starr T, Wallis SC, Roberts JA (2014) Risk factors for target non-attainment during empirical treatment with beta-lactam antibiotics in critically ill patients. Intensive Care Med 40:1340–1351
34. Jamal JA, Roberts DM, Udy AA, Mat-Nor MB, Mohamad-Nor FS, Wallis SC, Lipman J, Roberts JA (2015) Pharmacokinetics of piperacillin in critically ill patients receiving continuous venovenous haemofiltration: a randomised controlled trial of continuous infusion versus intermittent bolus administration. Int J Antimicrob Agents 46:39–44
35. Jamal JA, Mat-Nor MB, Mohamad-Nor FS, Udy AA, Wallis SC, Lipman J, Roberts JA (2015) Pharmacokinetics of meropenem in critically ill patients receiving continuous venovenous haemofiltration: a randomised controlled trial of continuous infusion versus intermittent bolus administration. Int J Antimicrob Agents 45:41–45
36. Hsaiky L, Murray KP, Kokoska L, Desai N, Cha R (2013) Standard versus prolonged doripenem infusion for treatment of gram-negative infections. Ann Pharmacother 47:999–1006
37. Bauer KA, West JE, O’Brien JM, Goff DA (2013) Extended-infusion cefepime reduces mortality in patients with Pseudomonas aeruginosa infections. Antimicrob Agents Chemother 57:2907–2912
38. Mustafa M, Chan WM, Lee C, Harijanto E, Loo CM, Van Kinh N, Anh ND, Garcia J (2014) A PROspective study on the usage patterns of doripenem in the Asia–Pacific region (PROUD study). Int J Antimicrob Agents 43:353–360
39. Carlier M, Dumoulin A, Janssen A, Picavet S, Vanthuyne S, Van Eynde R, Vanholder R, Delanghe J, De Schoenmakere G, De Waele JJ, Hoste EA (2015) Comparison of different equations to assess glomerular filtration in critically ill patients. Intensive Care Med 41:427–435
40. Roberts JA, Paul SK, Akova M, Bassetti M, De Waele JJ, Dimopoulos G, Kaukonen KM, Koulenti D, Martin C, Montravers P, Rello J, Rhodes A, Starr T, Wallis SC, Lipman J (2014) DALI: defining antibiotic levels in intensive care unit patients: are current beta-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis 58:1072–1083